1Cleeman JI. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ) .JAMA, 2001; 285: 2486 ～ 2497 被引量：1
2The Scandinavian Simvastatin Survival Study Group. Randomised trial of lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344:1383 ～ 1389 被引量：1
3Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastin in men with hypercholeterolemia. N Engl J Med,1995;333:1301 ～ 1307 被引量：1
4Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996; 335:1001 ～ 1009 被引量：1
5The Long - Term Intervention with Pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial choleesterol levels. N Engl J Med, 1998; 339:1349 ～ 1357, 1383 被引量：1
6Doans JR, Clearfield M, Whitey E, et al. Primary prevention acute coronary events with lovastatin in men and women with aeverage cholesterol levels.Results of AFCAPS/TexCAPS. JAMA, 1998;279:1615 ～ 1622 被引量：1
